Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Therapix Biosciences Ltd ADR TRPXY

Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid... see more

OTCPK:TRPXY - Post Discussion

View:
Post by StuinSea on Mar 28, 2019 9:12am

More News

https://seekingalpha.com/news/3446463-therapix-bio-18-percent-pricing-registered-direct-offering?dr=1#email_link

Therapix Bio down 18% on pricing registered direct offering

|About: Therapix Biosciences Ltd. (TRPX)|By:, SA News Editor

Therapix Biosciences (NASDAQ:TRPX) has entered into definitive agreements with several institutional investors providing for the issuance of an aggregate of 642,853 ADS at a price of $3.50/ADS in a registered direct offering.

Additionally, in a concurrent private placement, the Company will issue warrants to purchase up to 482,139 ADSs. The warrants will have a term of 3 years, with an exercise price of $3.50/ADS.

Expected gross proceeds are ~$2.25M. Net proceeds will be used for general corporate, product development purposes and the repayment of a portion of outstanding debt.

Closing date is April 1.

Shares are down 18% premarket.

Comment by Fundy13 on Mar 28, 2019 10:52am
Another short term band aid, not what I wanted to see. If they were gong to do financing I thought it would be for enough to get them through a couple years of research.  This is just another 3-6 month fix.  Not a good deal for current shareholders. The last round of financing they did was very good terms, this sucks.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities